COMPOUNDS / EMPATHOGEN / MDMA
EMPATHOGEN

MDMA

HIGH RISK
BEST FOR:PTSD Therapy●●●●●●●○○○7/10
MDMA · ECSTASY · MOLLY · 3,4-METHYLENEDIOXYMETHAMPHETAMINE · XTC · E · ADAM · MANDY
EmpathogenSerotoninNeurotoxicityParty DrugPTSD ResearchAmphetamine

A synthetic amphetamine analogue that preferentially releases serotonin, producing empathogenic and stimulant effects with documented neurotoxic potential.

ROUTE / DOSAGE
LOW20-80mg
STANDARD80-120mg
HIGH120-150mg+
Note: Therapeutic PTSD sessions use 80-120mg with optional supplemental dose of 40-60mg after 1.5-2h
CYCLE
Max 1x per month no daily use
BIOAVAILABILITY
~70-80% oral
ACTIVE DURATION
3-6h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
7-9h (plasma)
DURATION BREAKDOWN
Total3-6 hours
Onset30-45 min
Come up15-30 min
Peak1.5-3 hours
Offset1-2 hours
After effects2-24 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Elevated mood and empathy
Increased sociability and bonding
Enhanced tactile sensitivity
Increased energy and alertness
Mild visual and auditory distortions
Jaw clenching and bruxism
Reduced appetite
Altered time perception
§ 02 — RISKS
Serotonergic and dopaminergic neurotoxicity with potential long-term damage to the serotonergic system
Acute and life-threatening toxicity from drug interactions, particularly with CYP2D6-metabolized substances
Development of substance use disorder in some individuals
Bruxism, anxiety, jitteriness, headache, and nausea commonly reported
Neuroinflammatory effects on central dopaminergic and serotonergic neurons
Increased risk of adverse events in uncontrolled or non-therapeutic settings
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
CAUTION
5-MeO-xxT
Alcohol
Cocaine
DOx
GHB
GBL
MXE
ΑMT
Protease Inhibitors
SSRIs
SNRIs
AVOID · DANGEROUS
Tramadol
MAOIs
DXM
25x-NBOMe
PCP
Serotonin releasers
2C-T-x
5-HTP
§ 04 — SCIENCE

Preclinical and clinical studies demonstrate that MDMA can elicit acute and persistent central abnormalities of varying severity, with neurotoxic effects on dopaminergic and serotonergic neurons demonstrated in experimental animals. MDMA-assisted psychotherapy has shown therapeutic potential for PTSD, with meta-analyses indicating significant reductions in CAPS scores compared to control psychotherapy, though statistical heterogeneity is high and risk of bias in trials is a concern. Side effects in clinical trials are largely transient and mild to moderate in severity, but evidence quality ranges from very low to moderate per GRADE assessment. MDMA-drug interactions are clinically significant, particularly with CYP2D6-metabolized pharmaceuticals due to MDMA's inhibitory action, and repeated MDMA administration increases interaction risk. Long-term damage to the serotonergic system has been reported, though further investigation is needed.

§ 06 — SOURCES
[1]
MDMA interactions with pharmaceuticals and drugs of abuse
pubmed.ncbi.nlm.nih.gov ↗
[2]
Neurotoxicity of MDMA: Main effects and mechanisms
pubmed.ncbi.nlm.nih.gov ↗
[3]
MDMA-Assisted Psychotherapy for Treatment of PTSD: A Systematic Review With Meta-Analysis
pubmed.ncbi.nlm.nih.gov ↗
[4]
MDMA-assisted therapy for PTSD
pubmed.ncbi.nlm.nih.gov ↗
[5]
MDMA related neuro-inflammation and adenosine receptors
pubmed.ncbi.nlm.nih.gov ↗
[6]
Mephedrone and MDMA: A comparative review
pubmed.ncbi.nlm.nih.gov ↗
[7]
Side-effects of MDMA-assisted psychotherapy: a systematic review and meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[8]
MDMA: Serotonergic and dopaminergic mechanisms related to its use and misuse
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - MDMA
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT